Chidozie Ugwumba Sells 32,705 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 32,705 shares of Clene stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $5.50, for a total value of $179,877.50. Following the sale, the insider directly owned 708,587 shares in the company, valued at approximately $3,897,228.50. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $56,900.25.
• On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The stock was sold at an average price of $6.09, for a total value of $19,457.55.
• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total value of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total transaction of $18,790.44.
• On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The shares were sold at an average price of $5.87, for a total transaction of $34,451.03.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total transaction of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total transaction of $76,081.95.
• On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The shares were sold at an average price of $6.03, for a total transaction of $24,952.14.
• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total value of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $42,830.37.

Clene Stock Down 1.5%

NASDAQ:CLNN opened at $5.10 on Wednesday. The business’s 50 day moving average is $7.43 and its two-hundred day moving average is $6.46. Clene Inc. has a 52 week low of $2.28 and a 52 week high of $13.50. The company has a market cap of $55.34 million, a PE ratio of -1.50 and a beta of 0.87.

Clene (NASDAQ:CLNN) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. As a group, sell-side analysts expect that Clene Inc. will post -5.19 EPS for the current fiscal year.

Key Headlines Impacting Clene

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Director David J. Matlin bought 33,333 shares at an average $6.50, increasing his stake by ~7.5% — a management buy that can signal confidence in the stock and upcoming catalysts. SEC Filing
• Positive Sentiment: Clene announced additional CNM‑Au8 biomarker data and that the FDA granted an in‑person Type C meeting later this quarter — a clinical/regulatory milestone that could support a potential NDA path and act as a near‑term catalyst if data or FDA feedback is favorable. GlobeNewswire Release
• Neutral Sentiment: Reported short interest data shows effectively zero shares and a 0.0 days‑to‑cover metric (the report contains anomalous/NaN values) — not currently a clear driver of pressure or squeeze risk. (Reported Jan 12)
• Neutral Sentiment: Analyst and institutional profile is mixed: multiple buy ratings and a high consensus price target sit against modest institutional ownership (~23%) and weak recent revenue/earnings — these set expectations but are not an immediate price trigger. MarketBeat Profile
• Negative Sentiment: Major shareholder Chidozie Ugwumba has executed a series of sales since late December (including 32,705 shares on Jan 12 and multiple smaller lots), reducing his position by several percent overall — sustained insider selling at recent prices can create downward pressure and prompt investor concern. InsiderTrades Report

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Benchmark reaffirmed a “buy” rating on shares of Clene in a research report on Thursday, December 4th. UBS Group reaffirmed a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a research report on Friday. Finally, D. Boral Capital reissued a “buy” rating and issued a $23.00 price target on shares of Clene in a report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Clene presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CLNN. Scoggin Management LP lifted its holdings in Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after purchasing an additional 107,250 shares during the period. Lunt Capital Management Inc. raised its position in shares of Clene by 71.2% during the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after buying an additional 21,217 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Clene during the 2nd quarter worth about $47,000. Finally, Jones Financial Companies Lllp acquired a new stake in shares of Clene in the 3rd quarter worth approximately $29,000. 23.28% of the stock is owned by institutional investors and hedge funds.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).